Genetron Holdings ( ) - 株価, ニュースと分析Nasdaq:GTH

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

GTH 株式概要

Genetron Holdings Limited, a precision oncology platform company, focuses on cancer management by utilizing technologies in molecular biology and data science in the People’s Republic of China.

会社概要

GTH fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

報酬

過去 1 年間で収益は22.3%増加しました

リスク分析

最新の財務報告は6か月以上前のものである

過去1年間で株主の希薄化が進んだ

Genetron Holdings Limited 競合他社

Adlai Nortye

NasdaqGM:ANL

US$124.4m

Werewolf Therapeutics

NasdaqGS:HOWL

US$130.8m

LakeShore Biopharma

NasdaqCM:LSB

US$131.4m

Karyopharm Therapeutics

NasdaqGS:KPTI

US$119.2m

価格と性能

Summary of all time highs, changes and price drops for Genetron Holdings
Historical stock prices
Current Share Price	US$4.03
52 Week High	US$4.05
52 Week Low	US$2.08
Beta	0.50
1 Month Change	2.68%
3 Month Change	9.38%
1 Year Change	37.59%
3 Year Change	-93.70%
5 Year Change	n/a
Change since IPO	-91.61%

Recent updates

Genetron Holdings Limited's (NASDAQ:GTH) Intrinsic Value Is Potentially 24% Below Its Share Price

Aug 17

Genetron Holdings Limited (NASDAQ:GTH) Released Earnings Last Week And Analysts Lifted Their Price Target To US$26.22

Mar 27

Is Genetron Holdings Limited (NASDAQ:GTH) Popular Amongst Insiders?

Feb 25

Genetron Health, Sino Biopharm's subsidiary inks strategic partnership for HCCscreen in China

Jan 06

Genetron up 2% after HCCscreen selected by NCC, Wuxi for public health initiative in China

Nov 27

Genetron (GTH) Investor Presentation - Slideshow

Nov 18

Genetron Holdings reports Q3 results

Nov 09

株主還元

	GTH	US Biotechs	US 市場
7D	0.1%	-2.0%	1.6%
1Y	37.6%	5.4%	21.5%

業界別リターン: GTH過去 1 年間で8.4 % の収益を上げたUS Biotechs業界を上回りました。

リターン対市場: GTH過去 1 年間で21.8 % の収益を上げたUS市場を上回りました。

価格変動

Is GTH's price volatile compared to industry and market?
GTH volatility
GTH Average Weekly Movement	1.6%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

安定した株価: GTH過去 3 か月間に大きな価格変動はありませんでした。

時間の経過による変動: GTHの週次ボラティリティ ( 2% ) は過去 1 年間安定しています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2013	993	Sizhen Wang	www.genetronhealth.com

Genetron Holdings Limited 基礎のまとめ

Genetron Holdings の収益と売上を時価総額と比較するとどうか。
GTH 基礎統計学
時価総額	US$127.29m
収益（TTM）	-US$111.74m
売上高(TTM)	US$89.95m

1.4x

P/Sレシオ

-1.1x

PER（株価収益率

GTH は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
GTH 損益計算書（TTM）
収益	CN¥650.71m
売上原価	CN¥369.28m
売上総利益	CN¥281.43m
その他の費用	CN¥1.09b
収益	-CN¥808.40m

直近の収益報告

Dec 31, 2022

次回決算日

該当なし

一株当たり利益（EPS）	-25.56
グロス・マージン	43.25%
純利益率	-124.23%
有利子負債／自己資本比率	15.7%

GTH の長期的なパフォーマンスは？

過去の実績と比較を見る

GTH 株式概要

報酬

リスク分析

Genetron Holdings Limited 競合他社

NasdaqGM:ANL

US$124.4m

NasdaqGS:HOWL

US$130.8m

NasdaqCM:LSB

US$131.4m

NasdaqGS:KPTI

US$119.2m

価格と性能

最新ニュース

Genetron Holdings Files Form 15

Genetron Holdings Requests Nasdaq to File Form 25 with the Securities and Exchange Commission for Delisting of the ADSs on Nasdaq and the Deregistration of its Registered Securities

New minor risk - Shareholder dilution

Genetron Health Announces Receipt of Notification from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement of its American Depositary Shares

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Genetron Health Regains Compliance with Nasdaq Minimum Bid Price Requirement

Recent updates

Genetron Holdings Files Form 15

Genetron Holdings Requests Nasdaq to File Form 25 with the Securities and Exchange Commission for Delisting of the ADSs on Nasdaq and the Deregistration of its Registered Securities

New minor risk - Shareholder dilution

Genetron Health Announces Receipt of Notification from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement of its American Depositary Shares

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Genetron Health Regains Compliance with Nasdaq Minimum Bid Price Requirement

Less than half of directors are independent

Genetron Health Announces Receipt of Notification from Nasdaq Regarding Minimum Bid Price

Second quarter 2022 earnings released: CN¥2.54 loss per share (vs CN¥1.00 loss in 2Q 2021)

Genetron Holdings GAAP EPS of -$0.08, revenue of $20.56M

Sizhen Wang made a non binding proposal to acquire the remaining 49.2% stake in Genetron Holdings Limited (NasdaqGM:GTH) from Genetron Health (Hong Kong) Company Limited and others for $60 million.

China's Genetron gets acquisition offer from co-founder/CEO

Genetron Holdings Limited to Report Q1, 2022 Results on Jun 02, 2022

Full year 2021 earnings: EPS misses analyst expectations

Price target decreased to US$6.51

Consensus EPS estimates fall by 24%

Less than half of directors are independent

Consensus EPS estimates fall by 24%

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations

Genetron Holdings Limited Reports Impairment Charges for the Fourth Quarter Ended December 31, 2021

Genetron Holdings Limited Reiterates Full Year 2021 Revenue Guidance

Chief Technology Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Are Investors Undervaluing Genetron Holdings Limited (NASDAQ:GTH) By 27%?

Chief Financial Officer notifies of intention to sell stock

Third quarter 2021 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Price target decreased to US$18.92

Genetron Holdings Limited Provides Revenue Guidance for the Full Year 2021

Price target decreased to US$22.63

Co-Founder notifies of intention to sell stock

Second quarter 2021 earnings released

Genetron Holdings Limited Maintains Revenue Guidance for the Year 2021

Genetron Holdings Limited's (NASDAQ:GTH) Intrinsic Value Is Potentially 24% Below Its Share Price

Genetron Health Limited Receives CE Mark for 8-Gene Lung Cancer Assay and Provides FDA Reference Panel Comparative Data of its SARS-CoV-2 RNA Test

Chief Operating Officer Ying Hong has left the company

Non-Executive Director Weidong Liu has left the company

Genetron Holdings Limited Reiterates 2021 Financial Guidance

First quarter 2021 earnings released: CN¥1.23 loss per share (vs CN¥4.62 loss in 1Q 2020)

Full year 2020 earnings released: CN¥50.92 loss per share (vs CN¥27.06 loss in FY 2019)

Consensus forecasts updated

Genetron Holdings Limited (NASDAQ:GTH) Released Earnings Last Week And Analysts Lifted Their Price Target To US$26.22

Genetron Holdings Limited Provides Revenue Guidance for Year 2021

Full year 2020 earnings released: CN¥50.92 loss per share (vs CN¥27.06 loss in FY 2019)

Genetron Holdings Limited to Report Q4, 2020 Results on Mar 25, 2021

Is Genetron Holdings Limited (NASDAQ:GTH) Popular Amongst Insiders?

New 90-day high: US$28.04

New 90-day high: US$23.47

Genetron Health Announces Exclusive Strategic Partnership with Chia Tai Tianqing Pharmaceutical Group Co., Ltd

Genetron Health, Sino Biopharm's subsidiary inks strategic partnership for HCCscreen in China

New 90-day high: US$14.00

Genetron Holdings Limited Provides an Update for Hccscreentm, Its Blood-Based Early Screening Test for Hepatocellular Carcinoma (“Hcc”), in China

Genetron up 2% after HCCscreen selected by NCC, Wuxi for public health initiative in China

New 90-day high: US$13.27

Genetron (GTH) Investor Presentation - Slideshow

Analysts increase EPS estimates to -CN¥10.14

Genetron Holdings reports Q3 results

Genetron Holdings Limited to Report Q3, 2020 Results on Nov 09, 2020